The study, which will add a total of 214 patients, will be prospective, randomized, single blinded, and executed at six participating centers. Mayo Clinic may be the managing site for the study and has chosen the six independent implanting sites which it’ll manage throughout the study including one located in Germany and five in the usa. The first individual enrollment can be targeted for the second half of 2011. OpRA III is certainly a powerful opioid receptor antagonist, with potential make use of in multiple therapeutic indications. Adolor intends to in the beginning develop OpRA III to treat opioid bowel dysfunction and will initiate scientific trials of the compound for this indication in early 2010. Moving forward, OpRA III will be identified as ADL5945. Dougherty, Chief and President Executive Officer of Adolor.Alexion isn’t issuing equity regarding the the acquisition. The transaction is subject to customary conditions, including the termination or expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Action. The Boards of both businesses have approved the purchase and the companies currently anticipate that the purchase will be completed in the first quarter of 2012. Alexion intends to financing the acquisition through cash readily available and $300 million of committed bank personal debt.